Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Xingfa Huo"'
Autor:
Xingfa Huo, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Qiqi Xie, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionMany systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases. However, it is unclear which pharmacological treatment option is the most beneficial.MethodsWe
Externí odkaz:
https://doaj.org/article/d3cdbd4c51a44552adbf87fb5fad421b
Autor:
Yi Zhao, Wenwen Wang, Jinming Li, Jiarui Du, Qiqi Xie, Miaozhou Wang, Zhen Liu, Xingfa Huo, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao, GuoShuang Shen
Publikováno v:
PLoS ONE, Vol 18, Iss 11, p e0263710 (2023)
α1C-tubulin (TUBA1C) is a member of the α-tubulin family and has served as a potential biomarker in a variety of cancers in many studies. In this study, the gene expression profile of TUBA1C in The Cancer Genome Atlas (TCGA) was extracted for analy
Externí odkaz:
https://doaj.org/article/58fad73c41e84296b9f1c60a551b3b30
Autor:
Yuanfang Xin, Guoshuang Shen, Yonghui Zheng, Yumei Guan, Xingfa Huo, Jinming Li, Dengfeng Ren, Fuxing Zhao, Zhen Liu, Zitao Li, Jiuda Zhao
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Purpose Some studies have shown that Immune checkpoint inhibitors (ICIs) have a favorable efficacy in advanced triple negative breast cancer (TNBC) patients, but the results are controversial in neoadjuvant chemotherapy (NACT) stage. The pur
Externí odkaz:
https://doaj.org/article/7e5c3c4c18ff45ae9e8fc223d09d5bf1
Autor:
Jin Zhang, Qiqi Xie, Xingfa Huo, Zhilin Liu, Mengting Da, Mingxue Yuan, Yi Zhao, Guoshuang Shen
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Breast cancer has a high mortality rate among malignant tumors, with metastases identified as the main cause of the high mortality. Dysbiosis of the gut microbiota has become a key factor in the development, treatment, and prognosis of breast cancer.
Externí odkaz:
https://doaj.org/article/da7b791d364649e0baa2e300975b066d
Publikováno v:
Journal of International Medical Research, Vol 50 (2022)
Persistent left superior vena cava (PLSVC) is a common venous variation that is usually accompanied by an absence of the left brachiocephalic vein, and displays a higher incidence in patients with congenital heart disease. Here, the case of a 57-year
Externí odkaz:
https://doaj.org/article/af720d5086774763aca3fa92913ae332
Autor:
Xingfa Huo, Jinming Li, Fuxing Zhao, Dengfeng Ren, Raees Ahmad, Xinyue Yuan, Feng Du, Jiuda Zhao
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background The role of capecitabine in neoadjuvant and adjuvant chemotherapy for early-stage triple-negative breast cancer (TNBC) is highly controversial. Our meta-analysis was designed to further elucidate the effects of capecitabine on sur
Externí odkaz:
https://doaj.org/article/1ffcf19110b84305a90fe7a516ce7377
Autor:
Fuxing Zhao, Xingfa Huo, Miaozhou Wang, Zhen Liu, Yi Zhao, Dengfeng Ren, Qiqi Xie, Zhilin Liu, Zitao Li, Feng Du, Guoshuang Shen, Jiuda Zhao
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionThe predictive strength and accuracy of some biomarkers for the pathological complete response (pCR) to neoadjuvant therapy for HER2-positive breast cancer remain unclear. This study aimed to compare the accuracy of the HER2-enriched subt
Externí odkaz:
https://doaj.org/article/90dda0e0392d4f99ac984d75b2726fd1
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundThis meta-analysis aimed to better elucidate the predictive value of human epidermal growth factor receptor 2 (HER2)-enriched subtype of pathological complete response (pCR) rate within HER2-positive breast cancer patients receiving neoadju
Externí odkaz:
https://doaj.org/article/1b99697697544ae6be5e4cebe7bf84f1
Autor:
Jiuda Zhao, Tianzhuo Wang, Guoshuang Shen, Jinming Li, Xingfa Huo, Miaozhou Wang, Zhen Liu, Fuxing Zhao, Dengfeng Ren
Publikováno v:
Current Cancer Drug Targets. 23:718-730
Background: The optimal second-line therapy for hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) advanced or metastatic breast cancer is yet to be established. Therefore, we conducted a network meta-analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6391a32f171fad363c488ec04fedc00
https://doi.org/10.2174/1568009623666230407101128
https://doi.org/10.2174/1568009623666230407101128
Autor:
Yonghui Zheng, Guoshuang Shen, Chengrong Zhang, Xingfa Huo, Yuanfang Xin, Qianqian Fang, Yumei Guan, Fuxing Zhao, Dengfeng Ren, Zhen Liu, Miaozhou Wang, Jiuda Zhao
Publikováno v:
Clinical and Experimental Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc9402d73afd11dd22abc9673dcf843d
https://doi.org/10.1007/s10238-023-01072-7
https://doi.org/10.1007/s10238-023-01072-7